NRX — Nurexone Biologic Cashflow Statement
0.000.00%
Last trade - 00:00- CA$60.75m
- CA$57.96m
Annual cashflow statement for Nurexone Biologic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.132 | -8.17 | -3.64 | -5.04 | -6.38 |
| Depreciation | |||||
| Non-Cash Items | — | 4.08 | 0.661 | 0.993 | 1.32 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.056 | 0.237 | 0.004 | -0.923 | 0.372 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.076 | -3.85 | -2.94 | -4.89 | -4.51 |
| Capital Expenditures | — | -0.052 | -0.12 | -0.649 | -0.055 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1.69 | -0.037 | 0.023 | -0.009 | 0 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.69 | -0.089 | -0.097 | -0.658 | -0.055 |
| Financing Cash Flow Items | 1.76 | 2.75 | 0.095 | 0.071 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.76 | 4.29 | 1.13 | 5.88 | 5.83 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.006 | 0.249 | -1.92 | 0.159 | 1.44 |